share_log

Baird Maintains Neutral on Cogent Biosciences, Raises Price Target to $10

Benzinga ·  Sep 5 19:31  · Ratings

Baird analyst Joel Beatty maintains Cogent Biosciences (NASDAQ:COGT) with a Neutral and raises the price target from $8 to $10.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment